肺癌与全世界的高死亡率有关。非小细胞肺癌（NSCLC）是肺癌的一个主要亚型。卡铂 (CBDCA) 加白蛋白结合型紫杉醇 (PTX) 已成为晚期不可切除 NSCLC 的标准治疗方法。然而，nab-PTX 治疗尚未确立为可切除局部晚期 (LA)-NSCLC 的标准疗法。我们进行了一项全面研究，涉及连续接受 nab-PTX 诱导治疗并随后进行手术切除的局部晚期 NSCLC 患者。 15 名局部晚期 NSCLC 患者接受了包括 nab-PTX 在内的诱导治疗，随后进行了手术切除。同步放化疗 (CRT) 包括每周给予 nab-PTX (50 mg/m2) 加 CBDCA（血浆浓度时间曲线下面积 (AUC) 2）和胸部放疗（50 Gy/25 次）。临床分期为如下：IIB (n =1)、IIIA (n =12) 和 IIIC (n =2)。与同步 CRT 之前的临床分期相比，73% (11/15) 的患者观察到降期。 7 名患者观察到药物不良反应。所有患者均进行了完全切除。预处理后重新评估病理分期，诊断为0期3例，IA1期6例，IA2期1例，IIIA期5例。既往治疗的病理效果如下：Ef3（n=3）、Ef2（n=9）和Ef1a（n=3）。nab-PTX诱导治疗的治疗效果良好。诱导 CRT，包括 nab-PTX，然后进行切除术，可能是局部晚期 NSCLC 的可行替代治疗选择。© 2024。作者。

Lung cancer is associated with a high mortality rate worldwide. Non-small-cell lung cancer (NSCLC) is a major subtype of lung cancer. Carboplatin (CBDCA) plus nab-paclitaxel (PTX) has become a standard treatment for advanced unresectable NSCLC. However, treatment with nab-PTX has not been established as a standard therapy for resectable locally advanced (LA)-NSCLC.We conducted a comprehensive study involving consecutive patients with locally advanced NSCLC who underwent induction therapy including nab-PTX followed by surgical resection. Fifteen patients with locally advanced NSCLC underwent induction therapy including nab-PTX followed by surgical resection. Concurrent chemoradiotherapy (CRT) consisted of weekly administration of nab-PTX (50 mg/m2) plus CBDCA (area under the plasma concentration time curve (AUC) 2) and thoracic radiotherapy (50 Gy/25 fractions).The clinical stages were as follows: IIB (n =1), IIIA (n =12), and IIIC (n =2). Downstaging was observed in 73% (11/15) of patients on comparison with the clinical stage before concurrent CRT. Adverse drug reactions were observed in seven patients. Complete resection was performed in all patients. The re-evaluated pathological stage after pretreatment was diagnosed as stage 0 in three patients, stage IA1 in six, stage IA2 in one, and stage IIIA in five. The pathological effects of previous therapy were as follows: Ef3 (n =3), Ef2 (n =9), and Ef1a (n =3).The therapeutic effect of induction therapy including nab-PTX was promising. Induction CRT, including nab-PTX, followed by resection, may be a viable alternative treatment option for locally advanced NSCLC.© 2024. The Author(s).